Patents by Inventor Laurence E. Burgess

Laurence E. Burgess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
    Patent number: 8404681
    Abstract: Compound that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods of inhibiting the DNA-PK biological activity, methods of sensitizing cells the agents that cause DNA lesions, and methods of potentiating cancer treatment are disclosed.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: March 26, 2013
    Assignee: Luitpold Pharmaceuticals, Inc.
    Inventors: James W. Halbrook, Edward A. Kesicki, Laurence E. Burgess, Stephen T. Schlachter, Charles T. Eary, Justin G. Schiro
  • Materials and methods to potentiate cancer treatment
    Patent number: 8242115
    Abstract: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: August 14, 2012
    Assignee: Luitpold Pharmaceuticals, Inc.
    Inventors: James Halbrook, Edward A. Kesicki, Laurence E. Burgess, Stephen T. Schlachter, Charles T. Eary, Justin G. Schiro, Hongmei Huang, Michael Evans, Yongxin Han
  • 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES
    Publication number: 20120101103
    Abstract: Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D2 (PGD2). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.
    Type: Application
    Filed: December 18, 2009
    Publication date: April 26, 2012
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Adam Cook, Kevin W. Hunt, Robert Kirk Delisle, Todd Romoff, Christopher T. Clark, Ganghyeok Kim, Christopher P. Corrette, George A. Doherty, Laurence E. Burgess
  • Kinase inhibitors and methods of use thereof
    Patent number: 8044083
    Abstract: The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: October 25, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Robert Groneberg, Laurence E. Burgess, Darren Harvey, Ellen Laird, Mark C. Munson, James P. Rizzi, Martha Rodriguez, Charles Todd Eary, Daniel John Watson
  • P38 inhibitors and methods of use thereof
    Patent number: 8026233
    Abstract: Compounds of formula (I): in which A, B, X, Ar1, R8 and R4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: September 27, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Mark C. Munson, Kevin W. Hunt, Christopher T. Clark, Ganghyeok Kim, Laurence E. Burgess, James P. Rizzi
  • SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
    Publication number: 20110118235
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: August 18, 2010
    Publication date: May 19, 2011
    Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES
    Publication number: 20110105463
    Abstract: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    Type: Application
    Filed: June 24, 2009
    Publication date: May 5, 2011
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Laurence E. Burgess, Christopher T. Clark, Adam Cook, Christopher P. Corrette, Robert Kirk DeLisle, George A. Doherty, Kevin W. Hunt, Todd T. Romoff
  • SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
    Publication number: 20110092485
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: August 18, 2010
    Publication date: April 21, 2011
    Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong Woon Yang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7732446
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formulae: where the substituents are as described herein.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: June 8, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen L. Gwaltney, Jeffrey A. Stafford, Michael B. Wallace, Laurence E. Burgess, Scott D. Cowen, Stephen S. Gonzales, Ellen R. Laird, Xiaodong Wang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7678909
    Abstract: Compounds are provided which may be used to inhibit DPP-IV comprising the formula: wherein the substituents are as described in the specification and claims.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: March 16, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Laurence E. Burgess, Scott D. Cowen, Stephen L. Gwaltney, II, Jeongboeb Seo, Jeffrey A. Stafford
  • Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
    Patent number: 7553842
    Abstract: Disclosed are compounds of the Formula I and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein. Such compounds are useful in the treatment of immunoregulatory and respiratory diseases in mammals. Also disclosed are methods of using such compounds in the treatment of immunoregulatory and respiratory diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: June 30, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Stephen T. Schlacter, John J. Gaudino, Laurence E. Burgess, Kevin W. Hunt
  • P38 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20090149443
    Abstract: Compounds of formula (I): in which A, B, X, Ar1, R8 and R4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.
    Type: Application
    Filed: March 27, 2007
    Publication date: June 11, 2009
    Inventors: Mark C. Munson, Kevin W. Hunt, Christopher T. Clark, Ganghyeok Kim, Laurence E. Burgess, James P. Rizzi
  • Kinase Inhibitors And Methods Of Use Thereof
    Publication number: 20090023795
    Abstract: The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.
    Type: Application
    Filed: January 26, 2007
    Publication date: January 22, 2009
    Inventors: Robert Groneberg, Laurence E. Burgess, Darren Harvey, Ellen Laird, Mark C. Munson, James P. Rizzi, Martha Rodriguez, Charles Todd Eary, Daniel John Watson
  • Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
    Patent number: 7226906
    Abstract: Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: June 5, 2007
    Assignee: Array BioPharma, Inc.
    Inventors: Kevin W. Hunt, Laurence E. Burgess
  • Materials and methods to potentiate cancer treatment
    Patent number: 7179912
    Abstract: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: February 20, 2007
    Assignee: ICOS Corporation
    Inventors: James Halbrook, Edward A. Kesicki, Laurence E. Burgess, Stephen T. Schlachter, Charles T. Eary, Justin G. Schiro, Hongmei Huang, Michael Evans, Yongxin Han
  • Dipeptidyl peptidase inhibitors
    Patent number: 7169926
    Abstract: Compounds are provided which may be used to inhibit DPP-IV comprising the formula: wherein the substituents are as described in the specification and claims.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: January 30, 2007
    Assignees: Takeda Pharmaceutical Company Limited, Array BioPharma Inc.
    Inventors: Laurence E. Burgess, Scott D. Cowen, Stephen L. Gwaltney, II, Jeongboeb Seo, Jeffrey A. Stafford
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6998416
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: February 14, 2006
    Assignee: Icos Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20040152754
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: January 15, 2004
    Publication date: August 5, 2004
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodie sterase inhibitors
    Patent number: 6716871
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: April 6, 2004
    Assignee: Icos Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E Burgess, John J. Gaudino, Zachary S Jones, Bradley J Newhouse, Stephen T. Schlachter
  • CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS
    Publication number: 20040023945
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: May 17, 2002
    Publication date: February 5, 2004
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter